biostudies-literatureMychaleckyj JCNIDDK NIH HHSS75-87https://www.ebi.ac.uk/biostudies/studies/S-EPMC2917849biostudies-literatureUnknown7(1 Suppl)<h4>Background</h4>Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers.<h4>Purpose</h4>In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years.<h4>MeClinical trials (London, England)HLA genotyping in the international Type 1 Diabetes Genetics Consortium.PMC2917849R01 DK061722U01 DK062418Pierce JJVarney MDRappner RMoonsamy PVT1DGCMychaleckyj JCLavant ELane JAAkolkar BBonella PWilliams DTHelmberg WErlich HAFear ALCarlson JALouey ATait BDPerdue LHSteffes MWSali PKim SNoble JAReboussin DMBoyle SPost JHilner JEfalseHLA genotyping in the international Type 1 Diabetes Genetics Consortium.<h4>Background</h4>Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loci in all affected sibling pair and trio families, and cases and controls, recruited from four networks worldwide, for analysis with clinical phenotypes and immunological markers.<h4>Purpose</h4>In this article, we present the operational strategy of training, classification, reporting, and quality control of HLA genotyping in four laboratories on three continents over nearly 5 years.<h4>Me2010-01-01T00:00:00Z20102025-04-05T09:55:50.944Z2019-06-06T22:16:46ZS-EPMC29178492059524310.1177/1740774510373494